Journal
JOURNAL OF DIABETES
Volume 5, Issue 4, Pages 378-390Publisher
WILEY
DOI: 10.1111/1753-0407.12057
Keywords
cancer; diabetes; diabetes treatment; epidemiology; randomized controlled trial
Categories
Funding
- Key Laboratory for Endocrine and Metabolic Diseases of Ministry of Health (China) [1994DP131044]
- Ministry of Health (China) [201002002]
- National Key New Drug Creation and Manufacturing Program of the Ministry of Science and Technology (China) [2012ZX09303006-001]
- 863 project [2012AA02A509]
Ask authors/readers for more resources
Diabetes and cancer are both heterogeneous and multifactorial diseases with tremendous impact on health worldwide. Epidemiologic evidence suggests that certain malignancies may be associated with diabetes, as well as with diabetes risk factors and, perhaps, with certain diabetes treatments. Numerous biological mechanisms could account for these relationships. Insulin-like growth factor (IGF)-1, IGF-2, IGF-1 receptors, insulin, and the insulin receptor play roles in the development and progression of cancers. Although evidence from randomized controlled trials does not support or refute associations of diabetes and its treatments with either increased or reduced risk of cancer incidence or prognosis, consideration of malignancy incidence rates and the magnitude of the trials that would be required to address these issues explains why such studies may not be readily undertaken.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available